Pregabalin Capsule
Product Images NDC 80425-0277

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0277). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description (Description)

Chemical structure of pregabalin showing its molecular configuration with amino and carboxyl functional groups and a branched hydrocarbon side chain.*

FDA Label Image

Label 1 (Pregabalin 80425 0277 03)

Pregabalin 100 mg capsule bottle label from Advanced Rx Pharmacy of Tennessee, LLC. The label shows the product name, strength, quantity (#90), a comparison to LYRICA, NDC numbers, lot number, and expiration date of 12/31/2025. Storage instructions and a barcode are also visible.*

FDA Label Image

Fig 1 (Fig 1)

A line graph illustrating the percent improvement in pain from baseline against the percent of patients improved. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The y-axis shows the percent of patients improved, ranging from 0 to 100, and the x-axis shows percent improvement in pain from baseline, also ranging from 0 to 100.*

FDA Label Image

Fig 10 (Fig 10)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR (likely a clinical event) over a period of 180 days between Pregabalin and Placebo groups. The y-axis shows estimated percentage from 0% to 100%, and the x-axis shows days from 0 to 180. Pregabalin shows a consistently higher percentage of subjects without LTR compared to Placebo throughout the timeline.*

FDA Label Image

Fig 11 (Fig 11)

A line graph showing the percent of subjects improved over a range of percent improvements from baseline to week 12 BOCF. It compares Pregabalin and placebo, with Pregabalin showing a higher percentage of subjects improved across the improvement range.*

FDA Label Image

Fig 12 (Fig 12)

A line graph comparing the percent of subjects improved from baseline to week 16 as measured by BOCF (Baseline Observation Carried Forward) between Pregabalin and Placebo. The x-axis represents percent improvement from 0% to 100%, and the y-axis shows percent of subjects improved from 0% to 100%. Two curves are shown: a solid line for Pregabalin and a dashed line for Placebo, with Pregabalin consistently showing higher percentages of subjects improved across the improvement range.*

FDA Label Image

Fig 2 (Fig 2)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It shows two lines: one for Pregabalin 100 mg three times a day and one for placebo, illustrating the differences in patient response to pain improvement.*

FDA Label Image

Fig 3 (Fig 3)

A line graph depicting the percent of patients improved plotted against percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, showing dose-related effects on pain improvement.*

FDA Label Image

Fig 4 (Fig 4)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The vertical axis shows percent of patients improved, and the horizontal axis represents percent improvement in pain, with data lines illustrating treatment responses over a range of pain improvement percentages.*

FDA Label Image

Fig 5 (Fig 5)

A line graph depicting percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows trends of patient improvement across different pain improvement percentages.*

FDA Label Image

Fig 6 (Fig 6)

A bar graph depicting responder rates (%) from two clinical studies, Study E1 and Study E3, comparing different dosages of pregabalin versus placebo. The graph shows increasing responder rates with higher dosages in both studies, with statistically significant differences noted against placebo at various dose levels.*

FDA Label Image

Fig 7 (Fig 7)

A line chart showing seizure reduction as median percentage change from baseline plotted against dose in mg/day. The chart compares four studies (E1 BD, E2 TID, E3 BD, E3 TID) with data points indicating significant p-values, demonstrating increasing seizure reduction with higher doses.*

FDA Label Image

Fig 9 (Fig 9)

A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. The graph compares four groups: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo. Each treatment group shows varying degrees of patient improvement percentages, with Pregabalin 800 mg showing the highest curve among the treatments.*

FDA Label Image

Formula (Formula)

A formula illustrating the calculation of creatinine clearance (CLcr), which factors in age, weight, serum creatinine levels, and applies a multiplication factor for female patients. This formula appears on a text panel, likely part of dosing or pharmacokinetic information related to Pregabalin capsules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.